Promotional information from Mundipharma Pharmaceuticals ltd.

References Prescribing information and adverse events reporting

Uncontrolled blood sugar
can't wait

INVOKANA (canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise.1

References

  1. Invokana Summary of Product Characteristics
  2. Davies M J, D'Alessio D A et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61(12):2461-2498
  3. Empagliflozin Summary of Product Characteristics
  4. Dapagliflozin Summary of Product Characteristics
  5. Lavalle-Gonzalez F J, Januszewicz A et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56(12):2582-2592
  6. Stenlof K, Cefalu W T et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15(4):372-382
  7. Wilding J P, Charpentier G et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67(12):1267-1282
  8. Forst T, Guthrie R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16(5):467-477
  9. Perkovic V, de Zeeuw D et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018;6(9):691-704
  10. Neal B, Perkovic V et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377(7):644-657
  11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853